Alliancebernstein L.P. Eiger Bio Pharmaceuticals, Inc. Transaction History

Alliancebernstein L.P.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$1.02 - $7.48 $7,446 - $54,604	7,300 Added 20.28%	43,300 $51,000
Q3 2022 Nov 15, 2022	BUY	$6.04 - $9.66 $16,912 - $27,048	2,800 Added 8.43%	36,000 $271,000
Q2 2022 Aug 15, 2022	BUY	$4.99 - $8.96 $18,962 - $34,048	3,800 Added 12.93%	33,200 $209,000
Q4 2021 Feb 14, 2022	SELL	$5.12 - $8.19 $9,728 - $15,560	-1,900 Reduced 6.07%	29,400 $153,000
Q2 2021 Jul 30, 2021	BUY	$7.82 - $9.23 $10,166 - $11,999	1,300 Added 4.33%	31,300 $267,000
Q2 2020 Aug 13, 2020	BUY	$5.4 - $13.37 $57,780 - $143,059	10,700 Added 55.44%	30,000 $288,000
Q1 2020 May 14, 2020	BUY	$4.91 - $14.7 $44,190 - $132,300	9,000 Added 87.38%	19,300 $131,000
Q3 2019 Nov 14, 2019	BUY	$9.59 - $12.0 $98,777 - $123,600	10,300 New	10,300 $106,000

748K

Ticker EIGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,966,800
Market Cap $76.1M
Description
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to ...

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

Stay updated on Alliancebernstein L.P. with notifications on news.